The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to ...

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

The EU Biotech Act was first spoken about in EC President Ursula von der Leyen's political guidelines for 2025 in July 2024.

Chiesi has entered an exclusive licence agreement with Aliada to develop ERTs using BBB-crossing technology for LSDs.

The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability ...

BostonGene and Kyoto University have collaborated to advance precision drug development for oesophageal squamous cell ...